AbbVie Inc. (LON:0QCV)

London · Delayed Price · Currency is GBP · Price in USD

225.25

-1.00 (-0.44%)

Feb 20, 2026, 5:09 PM GMT

14.17% (1Y)

Market Cap	294.62B +8.8%
Revenue (ttm)	45.44B +8.6%
Net Income	3.11B -1.2%
EPS	1.75 -1.3%
Shares Out	n/a
PE Ratio	94.73
Forward PE	15.44
Dividend	4.98 (2.21%)
Ex-Dividend Date	Jan 16, 2026

Volume	9,875
Average Volume	24,952
Open	224.01
Previous Close	226.25
Day's Range	223.00 - 228.17
52-Week Range	164.50 - 244.49
Beta	0.33
RSI	51.58
Earnings Date	Feb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 2012

Employees 55,000

Stock Exchange London Stock Exchange

Ticker Symbol 0QCV

Full Company Profile

Financial Performance

In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.23 billion, a decrease of -0.28%.

Financial numbers in USD Financial Statements